Diagonal Bio AB (publ) announced that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin is currently Diagonal Bio?s interim CEO. Karin Wehlin was elected to the Board of Directors of Diagonal Bio in the spring of 2023, and on November 23, 2023, she was appointed as interim CEO.

Karin holds an Executive MBA degree from Lund University and has completed education at INSEAD in Strategy, Innovation, and Leadership. She has over 25 years of experience in senior positions within the Life Science sector, and has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB. Karin has also worked as Manager in Corporate Finance and is the founder of EQL Pharma AB, where she served as the Executive Chairman of the board for 10 years.